Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
about
Tapentadol for chronic musculoskeletal pain in adultsOxycodone for neuropathic pain and fibromyalgia in adultsOpioids compared to placebo or other treatments for chronic low-back painOxycodone for neuropathic pain in adultsA Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal PainThe effect of journal impact factor, reporting conflicts, and reporting funding sources, on standardized effect sizes in back pain trials: a systematic review and meta-regressionEvolving paradigms in the treatment of opioid-induced bowel dysfunctionSystematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain managementNeuropathic cancer pain: What we are dealing with? How to manage it?Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled studyA Model-Based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-Malignant Pain.Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis.Tapentadol Prolonged Release for Chronic Pain: A Review of Clinical Trials and 5 Years of Routine Clinical Practice Data.Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended releaseDriving Ability in Patients with Severe Chronic Low Back or Osteoarthritis Knee Pain on Stable Treatment with Tapentadol Prolonged Release: A Multicenter, Open-label, Phase 3b Trial.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesEfficacy of duloxetine versus alternative oral therapies: an indirect comparison of randomised clinical trials in chronic low back pain.Combining opioid and adrenergic mechanisms for chronic pain.Comparison of the risks of shopping behavior and opioid abuse between tapentadol and oxycodone and association of shopping behavior and opioid abuse.Tapentadol in pain management: a μ-opioid receptor agonist and noradrenaline reuptake inhibitor.[Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].Tapentadol extended release in the management of peripheral diabetic neuropathic painA pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathyTapentadol in the management of chronic low back pain: a novel approach to a complex condition?Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.Lasting Prolonged-Release Tapentadol for Moderate/Severe Non-Cancer Musculoskeletal Chronic Pain.Severity of back pain may influence choice and order of practitioner consultations across conventional, allied and complementary health care: a cross-sectional study of 1851 mid-age Australian womenTapentadol for Cancer Pain Management: A Narrative Review.A comparison among tapentadol tamper-resistant formulations (TRF) and OxyContin® (non-TRF) in prescription opioid abusers.Patient considerations in the use of tapentadol for moderate to severe pain.Validity and responsiveness of EuroQol-5 dimension (EQ-5D) versus Short Form-6 dimension (SF-6D) questionnaire in chronic pain.Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis painPharmacological agents currently in clinical trials for disorders in neurogastroenterology.Efficacy and safety of nicoboxil/nonivamide ointment for the treatment of acute pain in the low back - A randomized, controlled trial.Opioid-induced constipation: challenges and therapeutic opportunities.Current considerations for the treatment of severe chronic pain: the potential for tapentadol.Tapentadol extended-release for treatment of chronic pain: a review.Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.New treatment options for chronic constipation: mechanisms, efficacy and safety.Tapentadol for pain: a treatment evaluation.
P2860
Q24187807-704F81BF-A5D4-4DCE-8132-8554BE23E2E6Q24193845-BE974D89-EBDE-401D-ADB3-20FF67AF32F7Q24200220-F9FE5F5E-4C6D-41B2-84F5-2ECF74DAF2D9Q26470985-84A5278B-18EB-49EA-A6B5-1B52D5DE11D3Q26739953-DD8E951D-4E60-4384-971C-329BD68FB4F8Q26775928-98EFE65D-D75F-48DD-9912-AB8CEE51F2E1Q26777692-EEC25E5C-F361-4953-A562-14ADF754CD26Q26853312-4CAC7CEC-6996-4DAD-B869-D85040DB0AF0Q26998945-C9112E0E-0D98-455B-97EB-F166826499A0Q28538067-BA9D4F79-7289-4CBD-B803-94CC5B769F16Q30487222-AB91ABE8-D641-4C52-A6F1-8C5B3879F51EQ30830216-685EB421-6C45-404F-8EDB-2DBE3B4D9969Q31128284-6D46BAAC-8953-48FD-AA5F-C0ED6858A79EQ33775071-36225663-B1BD-4F59-912B-2658AB8A5457Q33938745-E4FF2062-3B43-4C95-BE0B-D9382D3BCFA8Q34272502-B8B04FA1-F3F9-4279-8E13-BE7FFB259DA4Q34345461-B523B2D4-2B2E-41F7-8B8B-5CFFA4EFCA88Q34434307-C00B9BA1-611F-4CAE-9468-685188967032Q34512974-34E5C24A-11E8-442A-8AAB-D12425298687Q34628322-F5C3DC3D-D1C3-4BB1-8474-4A587A0A11AEQ34636179-28B986FE-C374-4010-8E1D-9C47FC36A0A3Q34982228-AFE9D9DD-893D-4A4C-A0EA-5D7E812A9DD9Q34990241-C385D27E-F642-4371-A677-1D3AFF15AEAEQ35178751-4F3E8892-93FA-47E8-8280-0973A83313EEQ35605900-7687DBE8-CA7C-4224-B6A9-9993A6F8E1EFQ35752535-66AD566C-AF31-42D1-AE63-77C0FDE8BF9BQ36136359-12718C22-0C2C-4B70-B507-C5F546ECABD2Q36248445-00CFDFC8-261E-419A-92F3-55FAAC402BB9Q36878938-BA39A022-C68E-44BB-9CD0-A860F290247FQ36991981-E66CA4D6-38AB-4499-A7A6-0F7D7747DEE0Q37042212-0626AD16-72D5-4AC4-85A2-20C8362607E0Q37115472-21CBFB45-C83F-4B27-861C-6ACB44DF30CDQ37200907-61F45557-2DC9-4817-96BD-7EBA4D23D19DQ37268887-E0340A59-B2C6-417B-B0CD-F61439ABC173Q37846099-7AECD5E5-C086-4D15-9DA1-7C15E9C0BD7DQ37907389-0CC78439-0B64-43EE-AF43-FEFBE427CD59Q37925605-5F4415AF-CE40-4D93-BBB4-DD481DF04551Q37954521-41C1746C-D526-4151-9531-8347B29DAD7FQ37960501-D15B85FD-3325-4FCA-A413-A6055E31A416Q37970786-A1532FD1-99CA-464A-83D8-367556B35646
P2860
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@en
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@nl
type
label
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@en
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@nl
prefLabel
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@en
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@nl
P2093
P2860
P921
P1476
Efficacy and safety of tapenta ...... ve-controlled Phase III study.
@en
P2093
Achim Steup
Akiko Okamoto
Bernd Lange
Claudia Lange
Douglas Y Shapiro
Ilse Van Hove
Mila Etropolski
Robert Buynak
P2860
P304
P356
10.1517/14656566.2010.497720
P407
P577
2010-08-01T00:00:00Z